Jing Wang, Ph.D.
Dr. Jing Wang joined Constellation in April 2019 with 13 years of translation and preclinical drug development experience in targeted cancer therapies and immune-oncology therapies. Most recently, Jing severed as Sr. Director, head of Niraparib Translational Research at TESARO (a GSK company) for 3 years. Her team was responsible for the translational research of TESARO’s PARP inhibitor, Niraparib (ZEJULA®) and supported ZEJULA® NDA + PMA co-filing and commercialization. Prior to TESARO, Jing spent 10+ year at Curis where she was the Head of Translational Biomarker and Preclinical Research. Her team was responsible for the development of several targeted or immune-oncology drug candidates targeting HDAC, PI3K, HSP90, IAP, EGFR, and PD-1. Jing received her Ph.D. in Biological Chemistry & Molecular Pharmacology from Harvard Medical School.